SIVA1 Knockdown Drives Aggressive Phenotypes in Triple-Negative Breast Cancer Cells while Enhancing Paclitaxel

Natália Sudan Parducci1, Bruna Oliveira de Almeida1, Anali Del Milagro Bernabe Garnique1

  • 1Department of Pharmacology, Institute of Biomedical Sciences, Universidade de São Paulo, São Paulo CEP 05508-900, Brazil.

ACS Omega
|July 10, 2026
PubMed

Insights

The study reveals SIVA1 protein overexpression in breast cancer promotes tumor growth and drug resistance. Inhibiting SIVA1 increases aggressiveness but enhances sensitivity to paclitaxel, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • SIVA1 is a multifunctional protein implicated in tumor progression.
  • Its specific role in breast cancer, despite frequent overexpression, is not well-defined.
  • Understanding SIVA1's molecular network is crucial for breast cancer research.

Purpose of the Study:

  • To elucidate the cellular mechanisms regulated by SIVA1 in breast cancer.
  • To characterize the molecular network associated with SIVA1.
  • To investigate the functional impact of SIVA1 on breast cancer cell behavior and drug sensitivity.

Main Methods:

  • Integrated in silico analyses and in vitro assays using breast cancer cell lines.
  • Assessment of cell proliferation, migration, invasion, and drug sensitivity in 2D and 3D models.
  • Molecular analyses of DNA damage, apoptosis, cytoskeletal regulators, ubiquitination, and p53 signaling.

Main Results:

  • SIVA1 overexpression is linked to pathways involved in protein secretion, DNA repair, and oxidative stress.
  • SIVA1 knockdown increased proliferation, migration, and invasion, but enhanced sensitivity to paclitaxel.
  • Knockdown led to increased DNA damage markers (γ-H2AX), apoptosis (cleaved PARP1), and altered p53 and Stathmin 1 signaling.

Conclusions:

  • SIVA1 is a key regulator of proliferation and cytoskeletal dynamics in breast cancer.
  • Inhibiting SIVA1 promotes a more aggressive phenotype but increases taxane sensitivity.
  • Findings suggest SIVA1's potential role in patient stratification and therapeutic decision-making for breast cancer treatment.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...